Literature DB >> 15346915

Early diagnosis of Maroteaux-Lamy syndrome in two patients with accelerated growth and advanced bone maturation.

Delphine Heron1, Clarisse Baumann, Jean Jacques Benichou, Jean Paul Harpey, Martine Le Merrer.   

Abstract

UNLABELLED: The diagnosis of mucopolysaccharidosis (MPS) VI is usually not made before the age of 2 or 3 years when the main clinical signs of dwarfed stature, skeletal deformities, coarsening facies, stiff joints and hepatosplenomegaly described in textbooks are recognisable. Conversely, accelerated growth with advanced bone age, a precocious feature of this condition although not suggestive of a storage disorder, is usually neither recognised, nor adequately interpreted. We report on two infants with MPS VI who presented with these two "unexpected" features within the 1st year of life.
CONCLUSION: Recognition of precocious excessive growth in a mucopolysaccharidosis enables an early diagnosis, the prime responsibility of the clinician, in order to propose early treatment like bone marrow transplantation or active recombinant sulphatase therapy, and appropriate genetic counselling.

Entities:  

Mesh:

Year:  2004        PMID: 15346915     DOI: 10.1007/s00431-004-1428-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  [A NEW DYSOSTOSIS WITH URINARY ELIMINATION OF CHONDROITIN SULFATE B].

Authors:  P MAROTEAUX; B LEVEQUE; J MARIE; M LAMY
Journal:  Presse Med       Date:  1963-09-25       Impact factor: 1.228

2.  Valvular heart disease in four patients with Maroteaux-Lamy syndrome.

Authors:  C T Tan; H V Schaff; F A Miller; W D Edwards; P S Karnes
Journal:  Circulation       Date:  1992-01       Impact factor: 29.690

3.  Chromosomal localization of ARSB, the gene for human N-acetylgalactosamine-4-sulphatase.

Authors:  T Litjens; E G Baker; K R Beckmann; C P Morris; J J Hopwood; D F Callen
Journal:  Hum Genet       Date:  1989-04       Impact factor: 4.132

4.  Diagnosis of Maroteaux-Lamy syndrome by the use of radiolabelled oligosaccharides as substrates for the determination of arylsulphatase B activity.

Authors:  J J Hopwood; H Elliott; V J Muller; G T Saccone
Journal:  Biochem J       Date:  1986-03-15       Impact factor: 3.857

5.  Clinical definition of the Hurler-Hunter phenotypes. A review of 50 patients.

Authors:  J G Leroy; A C Crocker
Journal:  Am J Dis Child       Date:  1966-12

6.  Mental retardation in a patient with Maroteaux-Lamy.

Authors:  S Vestermark; T Tønnesen; M S Andersen; F Güttler
Journal:  Clin Genet       Date:  1987-02       Impact factor: 4.438

7.  Mucopolysaccharidosis VI (Maroteaux-Lamy's disease).

Authors:  J W Spranger; F Koch; V A McKusick; J Natzschka; H R Wiedemann; H Zellweger
Journal:  Helv Paediatr Acta       Date:  1970-10

8.  Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation.

Authors:  W Krivit; M E Pierpont; K Ayaz; M Tsai; N K Ramsay; J H Kersey; S Weisdorf; R Sibley; D Snover; M M McGovern
Journal:  N Engl J Med       Date:  1984-12-20       Impact factor: 91.245

9.  An N-acetylgalactosamine-4-sulfatase mutation (delta G238) results in a severe Maroteaux-Lamy phenotype.

Authors:  T Litjens; C P Morris; E F Robertson; C Peters; K von Figura; J J Hopwood
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878

10.  Proceedings: The defect in Maroteaux-Lamy disease (mucopolysaccharidosis VI, subtype A): deficiency of N-acetylgalactosamine-4-sulfatase.

Authors:  J F O'Brien; J Spranger; M Cantz
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1974-10
View more
  5 in total

1.  Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome).

Authors:  Adrian Quartel; Christian J Hendriksz; Rossella Parini; Sue Graham; Ping Lin; Paul Harmatz
Journal:  JIMD Rep       Date:  2014-12-18

2.  Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.

Authors:  Celeste Decker; Zi-Fan Yu; Roberto Giugliani; Ida Vanessa D Schwartz; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; J Edmond Wraith; Michael Beck; Laila Arash; Maurizio Scarpa; David Ketteridge; John J Hopwood; Barbara Plecko; Robert Steiner; Chester B Whitley; Paige Kaplan; Stuart J Swiedler; Susan Conrad; Paul Harmatz
Journal:  J Pediatr Rehabil Med       Date:  2010

Review 3.  Failures of Endochondral Ossification in the Mucopolysaccharidoses.

Authors:  Zhirui Jiang; Sharon Byers; Margret L Casal; Lachlan J Smith
Journal:  Curr Osteoporos Rep       Date:  2020-10-16       Impact factor: 5.096

4.  Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI.

Authors:  Paul R Harmatz; Paula Garcia; Nathalie Guffon; Linda M Randolph; Renée Shediac; Elizabeth Braunlin; Ralph S Lachman; Celeste Decker
Journal:  J Inherit Metab Dis       Date:  2013-10-10       Impact factor: 4.982

5.  The constellation of skeletal deformities in a family with mixed types of mucopolysaccharidoses: Case report.

Authors:  Ali Al Kaissi; Jochen Hofstaetter; Gerlinde Weigel; Franz Grill; Rudolf Ganger; Susanne Gerit Kircher
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.